Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy Sells 5,000 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $57.03, for a total transaction of $285,150.00. Following the completion of the sale, the vice president now directly owns 33,492 shares of the company’s stock, valued at $1,910,048.76. The trade was a 12.99 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Patrick Lamy also recently made the following trade(s):

• On Monday, December 16th, Patrick Lamy sold 1,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $29.13, for a total value of $29,130.00.
• On Tuesday, December 10th, Patrick Lamy sold 925 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.79, for a total value of $28,480.75.

Akero Therapeutics Stock Up 4.9 %

NASDAQ AKRO traded up $2.53 on Wednesday, reaching $54.00. The company had a trading volume of 3,613,883 shares, compared to its average volume of 2,167,465. The firm has a market capitalization of $3.77 billion, a price-to-earnings ratio of -14.40 and a beta of -0.19. Akero Therapeutics, Inc. has a 1-year low of $15.32 and a 1-year high of $58.40. The company’s fifty day moving average is $29.31 and its 200-day moving average is $28.51. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25.

Akero Therapeutics (NASDAQ:AKRO) last released its earnings results on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). On average, research analysts forecast that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Akero Therapeutics

Large investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP increased its holdings in Akero Therapeutics by 54.4% in the 3rd quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock worth $226,554,000 after acquiring an additional 2,782,029 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Akero Therapeutics during the 3rd quarter valued at about $37,392,000. SG Americas Securities LLC boosted its position in Akero Therapeutics by 4,022.1% during the fourth quarter. SG Americas Securities LLC now owns 597,993 shares of the company’s stock valued at $16,636,000 after buying an additional 583,486 shares during the period. RTW Investments LP grew its holdings in shares of Akero Therapeutics by 9.0% in the third quarter. RTW Investments LP now owns 5,919,435 shares of the company’s stock worth $169,829,000 after purchasing an additional 487,450 shares during the last quarter. Finally, Janus Henderson Group PLC raised its position in Akero Therapeutics by 2.9% during the 3rd quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company’s stock valued at $203,053,000 after purchasing an additional 201,225 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on AKRO shares. Citigroup boosted their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday. HC Wainwright upped their price objective on Akero Therapeutics from $50.00 to $72.00 and gave the company a “buy” rating in a research report on Monday. Morgan Stanley upped their price target on shares of Akero Therapeutics from $46.00 to $96.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, Canaccord Genuity Group raised their price objective on Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.57.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.